MedTrace Logo

Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy

NCT03406169 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2018-01-23

No results posted yet for this study

Summary

The study is a prospective, randomized, double-blind, placebo-controlled drug study to evaluate the pattern of erectile function recovery after robotic assisted laparoscopic prostatectomy (RALP). We hope to illustrate that early and continuous therapy with either Sildenafil citrate or pentoxyfylline after nerve sparing RALP will promote improved erectile function.

Conditions

Interventions

DRUG

Sildenafil 25 MG Oral Tablet

twice a day dosing

DRUG

Pentoxifylline

400mg twice a day

OTHER

Placebo

placebo twice a day

Sponsors & Collaborators

  • Walter Reed National Military Medical Center

    collaborator FED

  • Brooke Army Medical Center

    lead FED

Principal Investigators

  • Kuwong B Mwamukonda, MD · Brooke Army Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
89 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-13
Primary Completion
2021-12-31
Completion
2022-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03406169 on ClinicalTrials.gov